Core Insights - Novo Nordisk's stock has experienced a significant decline due to the company's forecast of a sales and operating profit decrease of 5% to 13% for the year [1] Group 1: Company Performance - The decline in sales and operating profit is occurring despite the launch of an oral version of the popular weight-loss drug Wegovy [1] - Pricing pressures are anticipated following a Most Favored Nation deal, which may further impact the company's financial performance [1] Group 2: Market Context - The launch of the oral Wegovy pill is seen as a critical move for Novo Nordisk, but the market dynamics, including competition and regulatory challenges, could pose additional hurdles [1]

Core Viewpoint - GSK's stock has reached a 12-year high, driven by optimistic sales projections of nearly $55 billion in five years, despite the absence of a GLP-1 drug in the competitive weight-loss market [1] Group 1: Sales Projections - GSK anticipates sales to approach $55 billion within five years [1] - The company's CEO, Luke Miels, expressed caution regarding the crowded weight-loss drug market [1] Group 2: Recent Developments - GSK is acquiring Rapt Therapeutics for $2.2 billion, which has positively impacted Rapt's stock [1] - GSK's ADR has seen a composite rating climb to 96, indicating strong performance [1]

Market Overview - US stocks mostly fell as Wall Street assessed earnings and awaited Alphabet's results, with the S&P 500 down about 0.5% and the Nasdaq Composite down over 1.5% [1] - The Dow Jones Industrial Average rose 0.4% as investors shifted from tech stocks to blue-chip names [1] AI Impact on Tech Stocks - Wall Street is struggling due to fears of AI disruption, leading to a sell-off in software stocks that affected global markets [2] - Major tech stocks like Nvidia fell over 3%, Google dropped nearly 2%, Amazon slid over 2%, and Tesla sank more than 3% [2] Earnings and Market Sentiment - Even better-than-expected earnings are insufficient to convince the market unless companies can demonstrate that AI will be beneficial [3] - Advanced Micro Devices saw its shares plummet due to a weak sales outlook, raising concerns about its competitiveness against Nvidia [3] Labor Market Insights - An ADP report indicated that employers added only 22,000 jobs in January, significantly below the expected 45,000 [4] - The delay in federal jobs data has made private data increasingly important, with the official jobs report rescheduled for next Wednesday [4] Commodity Movements - Gold gained amid US-Iran tensions but fell back below $5,000 an ounce after a significant slump [5] - Bitcoin losses accumulated, trading near $72,000 at one point [5] Pharmaceutical Sector Performance - Eli Lilly's stock surged after a positive 2026 profit forecast driven by high demand for weight-loss drugs [6] - In contrast, Novo Nordisk's shares tumbled after it forecasted a steep drop in sales, shocking investors [6]

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant [1] - The FDA's complete response letter (CRL) indicated that while previous drug trials were acknowledged, additional evidence of effectiveness was required for a favorable benefit-risk assessment [2] - Following the FDA's announcement, Corcept's stock price experienced a significant drop of $31.42, representing a 44.76% decrease, opening at $38.78 per share [2] Company Performance - The stock price decline marks a new 52-week low for Corcept, reaching levels not seen since September 2024 [3] - The investigation by Levi & Korsinsky LLP aims to assist investors who may have suffered losses in Corcept's securities [3] Legal Context - Levi & Korsinsky LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex securities cases [4]

Core Viewpoint - Eli Lilly and Company has issued a full-year revenue forecast that significantly exceeds analyst expectations, driven by strong demand for its weight-loss and diabetes treatments, resulting in an over 8% increase in shares during premarket trading [1] Group 1: Financial Performance - The company reported fourth-quarter revenue of $19.29 billion, marking a 43% year-over-year increase and surpassing Bloomberg consensus estimates of $18.01 billion [2] - Growth was primarily driven by strong volume increases in Zepbound and Mounjaro, which generated sales of $4.26 billion and $7.41 billion, respectively, both exceeding Wall Street forecasts [2] - U.S. volumes expanded by 50% during the quarter, contributing to a 43% increase in U.S. revenue, which reached $12.9 billion [2] Group 2: International Performance - Internationally, Mounjaro continued to support volume growth, partially offsetting pressures related to Jardiance, a diabetes drug developed in partnership with Boehringer Ingelheim [3] - International results were positively impacted by a one-time $300 million benefit tied to changes in the Jardiance collaboration during the quarter [3] Group 3: Future Guidance - The company has guided for full-year revenue between $80 billion and $83 billion, with earnings per share projected to be between $33.50 and $35.00 [4]

Core Insights - AbbVie Inc. reported fourth-quarter earnings and revenue that surpassed Wall Street expectations, driven by strong performance in its immunology and neuroscience segments, although shares fell over 2% in premarket trading after the announcement [1] Financial Performance - The company posted adjusted earnings per share of $2.71 for the quarter, exceeding the consensus estimate of $2.65 [2] - Revenue reached $16.62 billion, surpassing analyst expectations of $16.39 billion, reflecting a year-over-year growth of 10.0%, or 9.5% on an operational basis [2] Segment Performance - Immunology was the main growth driver, with global net revenues increasing by 18.3% to $8.63 billion [3] - Skyrizi generated $5.01 billion in sales, marking a 32.5% increase from the previous year, while Rinvoq contributed $2.37 billion, representing a growth of 29.5% [3] - Sales of Humira declined by 25.9% to $1.25 billion due to biosimilar competition, but the gains in Skyrizi and Rinvoq offset this decline [3] - The neuroscience portfolio also performed well, with revenue rising 17.9% to $2.96 billion [4] - Vraylar sales increased by 10.5% to $1.02 billion, and Botox Therapeutic revenue advanced by 13.4% to $990 million [4] - The oncology portfolio saw a slight decline of 1.5% to $1.66 billion, primarily due to a 20.8% drop in Imbruvica sales, although growth in Venclexta and Elahere partially offset this [4] Future Guidance - AbbVie provided full-year 2026 adjusted earnings guidance of $14.37 to $14.57 per share, which is above the analyst consensus of $14.22 [5]

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the company’s latest quarter, as he commented: This morning, Merck reported a very solid quarter, but gave what some people thought was a soft full-year forecast, yet the stock finished up the session more than 2%. Why? Because investors realized that the guidance was dragged down by one time costs related to a big acquisition last year. How could they not know that? This is one of my favorite pharmaceutical ...

Core Viewpoint - Glancy Prongay Wolke & Rotter LLP has initiated an investigation into Corcept Therapeutics Incorporated regarding potential violations of federal securities laws affecting investors [1] Company Summary - The investigation is on behalf of investors who may have incurred losses related to Corcept Therapeutics Incorporated (NASDAQ: CORT) [1]

In this articleLLYThe Eli Lilly and Novo Nordisk logos.Mike Blake | Tom Little | ReutersIt's a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, Lilly sees revenue jumping again thanks to its blockbuster medicines. The split in guidance – despite similar headwinds – underscores the strength of Lilly's position in the obesity and diabe ...

Core Insights - The competition in the GLP-1 market has intensified between Eli Lilly and Novo Nordisk following their recent fourth-quarter earnings reports [1] Eli Lilly's Performance - Eli Lilly has gained market leadership with its tirzepatide drugs, Mounjaro and Zepbound, which show superior weight loss efficacy of around 20% compared to semaglutide's 14% [2] - In the fourth quarter, Eli Lilly's revenue increased by 43% to $19.3 billion, surpassing consensus estimates of $17.9 billion, driven by a 46% volume growth despite a 5% decline in realized prices [7] - Mounjaro sales surged 110% to $7.4 billion, exceeding the forecast of $6.7 billion, while Zepbound revenue increased by 123% to $4.3 billion [8] - For 2026, Eli Lilly projects revenue growth of 27% to between $80 billion and $83 billion, above the consensus of $77.6 billion, with adjusted earnings expected to be between $33.50 and $35.00 per share [8] Novo Nordisk's Challenges - Novo Nordisk initially dominated the GLP-1 market but is now facing challenges, including a projected sales decline of 5% to 13% in 2026 at constant exchange rates, marking its first sales drop since 2017 [3][5] - The company reported 10% sales growth for 2025 at constant exchange rates, totaling 309 billion Danish kroner, which fell short of analysts' expectations of 347 billion kroner [4] - The fourth quarter showed an 8% revenue decline, although it slightly beat expectations, while earnings per share missed forecasts [4] - CEO Mike Doustdar cited U.S. pricing discounts, upcoming patent expirations for semaglutide, and competition from Lilly's Zepbound as reasons for the shortfall [5] Market Dynamics - Both companies face common challenges such as pricing pressures, competition, and patent risks, but their trajectories are diverging significantly [9] - Eli Lilly's pipeline, including the anticipated approval of orforglipron in Q2, positions it for sustained strength in the market [10] - Novo Nordisk is attempting to counteract pricing pressures with the launch of an oral version of Wegovy, which has shown early signs of success [6]